Expert Financial Analysis and Reporting

Investment Thesis Cytokinetics looks to me to be seriously undervalued when I contrast its market value (stock price multiplied by shares outstanding) of $430 million to that of other early stage biotechnology companies. In this note I look at key investment attributes of CYTK in comparison to those of a number of other biotechnology companies […]

Overview Windtree held a conference call on October 25 to update investors on the status of the phase 2a trial of Aerosurf and to discuss a trial that investigated the distribution of Aerosurf in the lungs of non-human primates. Management has consistently underestimated the time that it will take to complete the phase 2a trial. […]

Key Points; The most important data point between now and yearend 2016 is release of data from ZUMA-1 that shows whether the CR rate for KTE-C19 in r/r DLBCL remains unchanged at 33% over time. This is the expectation of key analysts and management. If it comes in meaningfully below that rate, the stock could […]

Key Points: Data for DCVax Direct recently was updated for its phase 1/2 trial in 40 patients having 13 different types of inoperable solid tumors. A scientific paper showed that the top 12 patients (30%) experienced overall survival of 22 months or longer. This was an open label trial without a control group as is […]

Overview Kite released a press release with topline data on the interim look at the ZUMA-1 trial. This note interprets information presented in that press release and I would urge you to read it before going on. Key Points: The CR rate at three months for 51 r/r DLBCL patients was 33%. Kite has said […]

Investment Opinion Kite will be reporting interim results of the phase 2, ZUMA-1 trial of its lead product KTE-C19 by the end of September. The most bullish analysts are projecting a very positive outcome in this trial that will result in approval in 2017 and sales of as much as $1 billion of sales by […]

Overview and Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and the thinking behind this was explained in my April 22 report An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92) The stock […]

Key Points: I think that an imminent press release dealing with topline results from an interim look at the ZUMA-1 trial will not have much meaningful data even though it is highly anticipated by investors. We will have to wait for the full data set that will be presented at American Society of hematology (ASH) […]

Report Overview This is the third part of the series of reports that I have written on Kite Pharmaceuticals. I have chosen to publish smaller, more digestible parts of an extensive research analysis on Kite instead of one huge report. I hope this will make it easier for subscribers to work their way through what […]

Overview This section tries to give a brief, layman’s overview on the potential role of CAR-T cells in treating certain hematological cancers and the competitive dynamics for companies operating in this space. Kite’s first product is the CAR-T drug KTE-C19. Key Points; There are three CAR-T drugs in development from Kite, Juno and Novartis. They […]